- Inmode revised its fiscal year revenue forecast down to a range of $410 million to $420 million, lower than the previous forecast of $430 million to $440 million.
- The revised revenue forecast also falls short of analysts’ expectations, which were estimated at $423.5 million.
- For the preliminary third quarter, Inmode’s revenue is reported to be between $130.0 million and $130.1 million, exceeding the estimate of $118 million.
- The revenue figure includes $31.9 million from pre-orders of a new platform delivered and recognized as income in the third quarter of 2024.
- Market sentiment for Inmode includes 2 buy ratings and 4 hold ratings, with no sell ratings.
A look at Inmode Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Investment analysts using Smartkarma Smart Scores have evaluated Inmode’s long-term outlook, factoring in key indicators such as Value, Dividend, Growth, Resilience, and Momentum. While the company scores moderately in Value and Growth, it excels in Resilience with a top score of 5. This suggests that Inmode is well-positioned to navigate challenges and maintain stability over the long term. However, the lower scores in Dividend and Momentum indicate some areas for potential improvement.
InMode Ltd. is a medical device development company known for its innovative radio-frequency based technology utilized by both patients and practitioners globally. With a balanced performance across various Smartkarma Smart Scores, Inmode demonstrates resilience amidst market shifts and shows promising potential for sustainable growth in the medical devices sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
